Title: Antibody Responses in Elderly Residential Care Persons following COVID-19 mRNA Vaccination

Authors: David A. Nace, MD, MPH^a, Kevin E. Kip, PhD^b, Octavia M. Peck Palmer, PhD^c, Michael R. Shurin, MD^c, Katie Mulvey, MT(ASCP)^d, Melissa Crandall, MT, MBA^d, April L. Kane, MSW, LSW^e, Amy Lukanski, DNP^f, Paula L. Kip, PhD^f, Alan L. Wells, MD, DMSc^{c,d} ^aDivision of Geriatric Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA ^bClinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA ^c Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA ^dClinical Laboratory, University of Pittsburgh Medical Center, Pittsburgh, PA, USA ^e Senior Services, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Corresponding author:

David A. Nace, MD, MPH University of Pittsburgh 3471 Fifth Avenue, Kaufmann Building, Suite 500 Pittsburgh, PA 15213 Email: naceda@UPMC.edu Phone: 412-692-2360

Keywords: COVID-19, SARS-CoV-2, mRNA vaccine, assisted living, independent living, personal care, reopening, quality improvement

1 ABSTRACT

2 **Objective**

- 3 COVID-19 disproportionately impacts older adults residing at long-term care facilities. Data
- 4 regarding antibody response to COVID-19 vaccines in this population is limited. Our objective
- 5 was to quantify the presence and magnitude of antibody response in older, vaccinated residents
- 6 at assisted living, personal care, and independent living facilities.

7 Design

- 8 A cross-sectional quality improvement study was conducted March 15 April 1, 2021 in the
- 9 Pittsburgh region.

10 Setting and Population

- 11 Participants were volunteers at assisted living, personal care, and independent living facilities,
- 12 who received mRNA COVID-19 vaccine. Conditions that obviate immune responses were
- 13 exclusionary criteria.

14 Methods

15 Sera were collected to measure IgG anti-SARS-CoV-2 antibody level with reflex to total anti-

16 SARS-CoV-2 immunoglobulin levels. Descriptive statistics, Pearson correlation coefficients, and

17 multiple linear regression analysis were performed to evaluate relationships between factors

18 potentially associated with antibody levels.

19 **Results**

- 20 All participants (N=70) had received two rounds of vaccination for COVID-19 and were found
- to have antibodies to SARS-CoV-2. There was wide variation in relative levels of antibodies as
- 22 determined by extinction coefficients. Antibody levels trended lower in male sex, advanced age,
- 23 steroid medications, and longer length of time from vaccination.

24 Conclusions and Implications

- 25 Higher functioning long-term care residents mounted detectable antibody responses when
- 26 vaccinated with COVID-19 mRNA-based vaccines. This study provides preliminary information
- 27 on level of population risk of assisted living, personal care, and independent living residents
- 28 which can inform reopening strategies. Data suggests some degree of immunity is present during
- 29 the immediate period following vaccination. However, protective effects of such vaccination
- 30 programs remain to be determined in larger studies. Clinical protection is afforded not just by
- 31 pre-formed antibody levels, but by ongoing adaptive immunity, which is known to be decreased
- in older individuals. Thus, the implications of these levels of antibodies in preventing COVID-19
- 33 disease must be determined by clinical follow-up.

34 INTRODUCTION

COVID-19 disproportionately impacts older adults and frail individuals residing in long-35 term care facilities. As of March 2021, there are over 1.4 million cases of COVID-19 in U.S. 36 37 nursing homes. In addition, over 175,000 COVID-19 related deaths have occurred, representing 34% of all U.S. COVID-19 deaths.¹ Advanced-age, high rates of frailty and comorbid conditions 38 along with close physical contact between residents and staff facilitate spread of the virus in 39 these settings. Visitor restrictions, curtailing of community dining, and other social activities 40 41 have been crucial to limiting spread of the virus. Between December 2020 and February 2021, the number of nursing home cases decreased by 80% and deaths by 65%, due in part to COVID-42 19 vaccinations.² Given the reductions in cases and severity, residents and families are now 43 calling for reopening of long-term care facilities to reduce the negative impacts of social 44 45 isolation on residents. The Centers for Medicare and Medicaid Services released guidance for reopening of nursing homes on March 10, 2021,³ but so far, no consensus exists around 46 47 reopening strategies for independent living, personal care, and assisted living facilities. 48 While current COVID-19 vaccines appear to be effective in reducing severe illness, 49 breakthrough cases do occur including asymptomatic infections. Age and frailty status are linked 50 to reduced vaccine response for other vaccines. Information regarding antibody response to 51 COVID-19 vaccines is limited. As part of an effort to assess level of risk in reopening strategies, 52 the Society for Post-Acute and Long-Term Care Medicine (AMDA), is recommending a 53 measured, stepwise approach to resuming visitation and group activities in post-acute and longterm care settings while acknowledging gaps in clinical knowledge about COVID-19.⁴ While 54 recommendations regarding reopening have been published,⁵⁻⁷ these focus on the process for 55 reopening and not risk assessment of the resident population. Antibody measurement may help 56 57 inform level of risk, particularly if significant numbers of individuals fail to demonstrate

antibody response. Therefore, the objective of this study was to quantify the presence and
magnitude of antibody response in older, vaccinated adults residing in assisted living, personal
care, and independent living facilities, including those with and without prior COVID-19
infection.

62 **METHODS**

63 Setting and Population

A cross-sectional quality improvement study was conducted March 15 – April 1, 2021 at 64 University of Pittsburgh Medical Center (UPMC) Senior Communities assisted living, personal 65 care, and independent living facilities in the Pittsburgh metropolitan region. Participants were 66 67 selected from volunteers at UPMC Senior Communities to determine antibody responses in the elderly. Participant eligibility criteria were residents who have received one or more doses of a 68 COVID-19 vaccine. Conditions that obviate immune responses were exclusionary criteria; these 69 70 were hematologic malignancies, solid organ transplants, active chemotherapy, and those that 71 require specific immunosuppressive therapies. Individuals receiving steroids at doses equivalent to less than 20 mg of prednisone daily or for less than ten-days duration were not excluded. This 72 73 project underwent review and was granted ethical approval as a quality improvement study by 74 the UPMC Quality Improvement Review Committee (Project ID: 3250), the ethics, regulatory, and legal oversight body for protecting patient/participant rights, confidentiality, consent 75 76 (including waiver of consent), and the analysis and dissemination of deidentified data within the 77 UPMC system.

78 Data Collection

79 Study data were collected and managed using the Research Electronic Data Capture
80 (REDCap) hosted at UPMC.⁸ REDCap is a secure, web-based software platform designed to

support data capture for research and quality improvement studies, providing 1) an intuitive
interface for validated data capture; 2) audit trails for tracking data manipulation and export
procedures; 3) automated export procedures for seamless data downloads to common statistical
packages; and 4) procedures for data integration and interoperability with external sources.⁹
Data was collected on vaccination status (number of doses, dates, and type of vaccine), medical
conditions, and current medications. Level of frailty was assessed in participants using selfreported activities of daily living and instrumental activities of daily living measures.¹⁰⁻¹²

88 Study Outcomes

To quantify the presence and magnitude of antibody response in this population, sera 89 were collected from each participant to measure IgG anti-SARS-CoV-2 antibody level with 90 91 reflex to total anti-SARS-CoV-2 immunoglobulin levels. SARS-CoV-2 antibody assays were 92 performed in the UPMC Clinical Laboratories at the Clinical Laboratory Building in Pittsburgh, PA. These are CLIA-88 accredited laboratories for clinical testing. The specimens were initially 93 94 assessed using the Beckman Coulter SARS-CoV-2 IgG Access assay (AU5800 analyzer, Brea, CA, USA), and then confirmed orthogonally using the Siemens Healthineers SARS-CoV-2 95 Total assay (ADIVA Centaur XP analyzer, Munich, Germany; Siemens-C).^{13,14} The Beckman 96 97 Coulter assay uses S1 Spike antigens as capture and anti-IgG as reporter; the Siemens uses S1 98 Spike antigens as both capture and reporter and thus IgM antibodies are detected and at a higher 99 molar 'index value' than IgG antibodies. Both assays were run according to the manufacturer's 100 instructions. Both assays use units that are generated by comparison to an internal calibrator or 101 standard, when referring to assay results collectively we refer to these units as 'index values' for simplicity; both use an index of >1.0 for positivity. 102

103 Statistical Methods

| 104 | Descriptive statistics for baseline population characteristics were calculated as means, |
|-----|--|
| 105 | standard deviations, and frequencies. Pearson correlation coefficients were calculated between |
| 106 | age and antibody level, and between days since vaccination and antibody level. We also |
| 107 | performed multiple linear regression modeling using stepwise entry criteria of $p < 0.20$ to |
| 108 | identify factors potentially associated with antibody levels. Analyses were performed using SAS, |
| 109 | version 9.4 (SAS Institute, Inc., Cary, NC). Methods and results are reported in accordance with |
| 110 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement ¹⁵ |
| 111 | and Standards for Quality Improvement Reporting Excellence (SQUIRE) guidelines |
| 112 | (Supplemental Table 1). ¹⁶ |
| 113 | RESULTS |
| 114 | Population |
| 115 | Presented in Table 1, a total of 70 volunteers participated, age range was 62-97 years old |
| 116 | with almost half in their 80s (49.3%) and the rest split between younger (22.5%) and older |
| 117 | (28.2%). Two-thirds were female (60%) and almost all participants were white (97.1%). The |
| 118 | frailty indices indicated moderate to high functioning. |
| 119 | Study Outcomes |
| 120 | All participants provided sera to be tested for antibodies to SARS-CoV-2, had undergone |
| 121 | two rounds of vaccination (Moderna 98.6%, Pfizer 1.4%) within the prior 50 days, and one in six |
| 122 | had recovered from COVID-19 infection (15.7%). Antibody levels were determined using two |
| 123 | FDA Emergency Use assays. All participants were found to have antibodies to SARS-CoV-2; |
| 124 | one was deemed non-reactive by the Beckman Coulter assay, having an extinction coefficient < |
| 125 | 1, but was assessed as reactive by the more sensitive ADIVA Centaur assay. ¹³ There is wide |
| 126 | variation in relative levels of antibodies as determined by extinction coefficients. While the |
| | |

| 127 | sample size is modest, which hinders statistical power, we found that antibody levels trended |
|-----|--|
| 128 | lower with male sex (standardized beta coefficient (β)=-0.11, p=.33) (Figure 1), advanced age |
| 129 | (β =-0,18, p=.11), current use of steroids (β =-0,22, p=.07), and longer length of time from |
| 130 | vaccination (β =-0.13, p=.28) (Figure 2). In participants who previously tested positive for |
| 131 | COVID-19 (n = 11), antibody levels trended higher (β =0.18, p=.12), though one participant had |
| 132 | very low levels of antibodies suggesting that prior infection does not guarantee a strong |
| 133 | response. |

134 DISCUSSION

The results indicate that UPMC Senior Communities assisted living, personal care, and independent living residents did mount a detectable level of antibody responses – though antibody levels varied significantly among the individuals. Demonstration of vaccine response in this population, along with observational data demonstrating reductions of COVID-19 following implementation of vaccination,² supports the argument for reopening facilities in the immediate period following vaccination.

This study has several limitations. Importantly, the presence of antibody levels does not 141 necessarily confirm immunity. As with other viral infections, immunity to SARS-CoV-2 142 infection is complex and influenced by B and T cell responses and the innate immune system.¹⁷ 143 Level of antibody, quality of antibodies produced, presence of neutralizing antibodies, and 144 duration of antibody presence are all important unknowns in this population.¹⁸ Thus, the 145 146 implications of these levels of antibodies in preventing COVID-19 disease must be determined by clinical follow-up, and incorporated into ongoing facility risk assessment as recommended.⁴ 147 148 The modest sample limits the precision in estimates and conclusions drawn, particularly in

stratified analyses. Participants were volunteers and likely to be healthier than non-participants,and individuals with known immunosuppression were excluded.

151 CONCLUSIONS/IMPLICATIONS

Published recommendations regarding reopening of post-acute and long-term care 152 settings focus on the process for reopening.³⁻⁸ Results from this study are part of an effort to 153 assess population level of risk in reopening strategies for the residents at assisted living, personal 154 care, and independent living facilities. The data reassures that moderate to higher functioning 155 156 adults, even of advanced age, do mount detectable antibody responses when vaccinated with 157 COVID-19 mRNA-based vaccines. These individuals demonstrate IgG within a range considered protective from other studies.¹⁴ This suggests that vaccination is functional and 158 159 appropriate in these individuals. However, protective effects of such vaccination programs in 160 advanced age residents at assisted living, personal care, and independent living facilities remain 161 to be determined in larger studies.

Acknowledgments: The authors thank the UPMC COVID-19 Antibody Work Team including but not limited to Debbie Albin, Derek C. Angus, Brian Bachowski, J. Ryan Bariola, Robert Bart, Lorraine Brock, Christian Carmody, Suzanne Colilla, Jeanne Cunicelli, Maris Dauer, Jonna R. Drost, Utibe Ralph Essien, Ghady Haidar, David Huang, Allison Hydzik, Matthias Kleinz, Gloria A. Kreps, Joon Sup Lee, Kelsey Linstrum, Holly L. Lorenz, Genna M. Mancine, Oscar Marroquin, Susan C. Martin, Rhonda Martini, Erin McCreary, Thomas McGough, Jeffery C. McKibben, Bryan J. McVerry, Heather Mediate, Russell Meyers, Tami Minnier, Stephanie Montgomery, Stacy Parker, Jeffery Porter, Kevin Quinn, Mark Schmidhofer, Christopher Seymour, Judy Shovel, Eileen Simmons, Graham Snyder, Colleen Sullivan, Richard J. Wadas, Knox Walk, Dean E. Walters, Mary Wisniewski, Paul C. Wood, Tabitha Wybiral, Donald Yealy, Wendy L. Zellner, and their entire teams.

Funding Statement:

This work received no external funding. Internal funding from the UPMC Hospital System had no control over the study.

Conflict of Interest Disclosure:

None of the authors received any payments or influence from a third-party source for the work presented, and none report any potential conflicts of interest.

References

- 1. Centers for Medicare & Medicaid Services. COVID-19 Nursing Home Data. Available at: https://data.cms.gov/stories/s/bkwz-xpvg. Accessed March 22, 2021.
- Conlen M, Mervosh S, Ivory D. Nursing homes, once hotspots, far outpace U.S. in COVID declines. Available at: https://www.nytimes.com/interactive/2021/02/25/us/nursing-home-covidvaccine.html#:~:text=The%20nursing%20homes%20that%20got,more%20have%20now %20been%20vaccinated_Accessed March 22, 2021.
- 3. Centers for Medicare & Medicaid Services. Nursing Home Visitation COVID-19 QSO-20-39-NH REVISED. Available at: https://www.cms.gov/files/document/qso-20-39-nh-revised.pdf._Accessed March 22, 2021.
- 4. American Medical Director Association. Interim recommendations for communal activities and visitation in post-acute and long-term care facilities. Available at https://paltc.org/sites/default/files/Interim%20Guidance%20for%20Communal%20Activi ties%20and%20Visitation%2025FEB2021%20-%20FINAL.pdf. Accessed April 2, 2021.
- 5. Bergman C, Stall NM, Haimowitz D, et al. Recommendations for welcoming back nursing home visitors during the COVID-19 pandemic: Results of a Delphi panel. J Am Med Dir Assoc 21; (2020):1759-1766. doi: https://doi.org/10.1016/j.jamda.2020.09.036.
- 6. Vipperman A, Zimmerman S, Sloane PD. COVID-19 recommendations for assisted living: Implications for the future. J Am Med Dir Assoc (2021). doi: https://doi.org/10.1016/j.jamda.2021.02.021. (Epub ahead of print).
- 7. Stall NM, Johnstone J, McGeer AJ, et al. Finding the right balance: An evidenceinformed guidance document to support the re-opening of Canadian nursing homes to family caregivers and visitors during the coronavirus disease 2019 pandemic. J Am Med Dir Assoc 21; (2020): 1365-1370. doi: https://doi.org/10.1016/j.jamda.2020.07.038.
- Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009 Apr;42(2):377-381. doi: https://doi.org/10.1016/j.jbi.2008.08.010
- 9. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software partners. J Biomed Inform 2019 May 9. doi: https://doi.org/10.106/j.jbi.2019.103208.
- 10. Katz S. Assessing self-maintenance: Activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 31;(12):721-726.

- 11. Katz S, Down TD, Cash HR, Grotz RC. Progress in the development of the index of ADL. Gerontologist 10;(1):20-30.
- 12. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 9;(3):179-186.
- 13. Zilla M, Wheeler BJ, Keetch C, et al. Performance of commercially available EUA SARS-CoV-2 antibody assays in critically ill and mildly symptomatic patients assessed at a large academic medical center. Am J Clin Pathol 155:343-353.
- 14. Zilla ML, Keetch C, Mitchell G, et al. SARS-CoV-2 serologic immune response in exogenously immunosuppressed patients. J Appl Lab Med 2021;6(2):486-490. doi: https://doi.org/10.1093/jalm/jfaa232.
- von Elm, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ 2007; 335(7624):806-808. doi: https://doi.org/10.1136/bmj.39335.541782.AD.
- 16. Ogrinc G, Davies L, Goodman D, et al. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): Revised publication guidelines from a detailed consensus process. BMJ Qual Saf 2015. doi: https://doi.org/10.1136/bmjqs-2015-004411
- 17. Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the Immune System. Physiol Res 2020;69:379-388. doi: https://doi.org/10.33549/physiolres.934492.
- Chowdhury MA, Hossain N, Kashem MA, et al. Immune response in COVID-19: A review. J Infection and Public Health 2020;13:1619-1629. doi: https://doi.org/10.1016/j.jiph.2020.07.001.

TABLES

Table 1. Descriptive Characteristics and Antibody Levels in Residents at Assisted Living, Personal Care, and Independent Living Facilities

| | All Patients | Female (N=42) | Male (N=28) | |
|--|--------------|---------------|-------------|--|
| | (N=70) | | | |
| Characteristic / Antibody level | (100%) | (60.0%) | (40.0%) | |
| Patient age in years, mean (SD) | 84.8 (7.8) | 84.6 (7.6) | 85.1 (8.3) | |
| Patient age in years, %, (n) | | | | |
| 62 to 79 years | 22.5 (16) | 21.4 (9) | 24.1 (7) | |
| 80 to 89 years | 49.3 (35) | 50.0 (21) | 48.3 (14) | |
| 90 to 97 years | 28.2 (20) | 28.6 (12) | 27.6 (8) | |
| Frailty, mean (SD) | | | | |
| Katz Index Independence ADL (scale 1-6) | 5.2 (1.4) | 5.2 (1.3) | 5.3 (1.5) | |
| Lawton Instrumental ADL (scale 1-6) | 5.3 (2.4) | 5.4 (2.3) | 5.1 (2.7) | |
| Previously told had COVID-19, %, (n) | 15.7 (11) | 11.9 (5) | 21,4 (6) | |
| Currently taking a steroid medication, %, (n) | 8.6 (6) | 9.5 (4) | 7.1 (2) | |
| Days from first vaccine to antibody sample, mean | 59.8 (13.5) | 58.9 (14.9) | 61.1 (11.1) | |
| (SD) | | | | |
| Days from second vaccine to antibody sample, | 32.3 (12.4) | 31.8 (13.2) | 33.0 (11.3) | |
| mean (SD) | | | | |
| ADIVA Centaur antibody determination, %, (n) | | | | |
| Low-responder (ADIVA Centaur <=10) | 7.0 (5) | 9.5 (4) | 3.4 (1) | |
| High-responder (ADIVA Centaur > 10) | 93.0 (66) | 90.5 (38) | 96.6 (28) | |
| Beckman Coulter antibody level, mean (SD) | 23.5 (15.4) | 24.3 (15.9) | 22.3 (14.8) | |
| Beckman Coulter antibody level, %, (n) | | | | |
| 0 to < 5 | 11.3 (8) | 7.1 (3) | 17.2 (5) | |
| 5 to 10 | 11.3 (8) | 14.3 (6) | 6.9 (2) | |
| More than 10 | 77.5 (55) | 78.6 (33) | 75.9 (22) | |

*ADL: Activities of Daily Living.

FIGURES




Figure 1. Scatter plot of patient age (x-axis) by Beckman Coulter antibody level (y-axis). Females (left plot) with red filled dots depicting participants without a prior history of COVID-19, and black filled rectangles depicting participants with a prior history of COVID-19. Males (right plot) with blue filled dots depicting participants without a prior history of COVID-19, and black filled rectangles depicting patients with a prior history of COVID-19.




Figure 2. Scatter plot of days since second vaccination (x-axis) by Beckman Coulter antibody level (y-axis). Blue filled dots depict patients without a prior history of COVID-19, and black filled rectangles depict patients with a prior history of COVID-19.

SUPPLEMENTAL TABLE

Table S1. Checklist: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and Standards for Quality Improvement Reporting Excellence (SQUIRE) 2.0 guidelines.

| | Item No. | STROBE items | Location in manuscript where items are reported | SQUIRE items | Location in manuscript where items are reported | | | | |
|-------------------------|-------------|---|--|---|---|--|--|--|--|
| Title and abstract | | | | | | | | | |
| | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Abstract, Pages 2-3 | Title: Indicate that the article concerns an initiative to improve healthcare. Abstract: This is a summary of your work and is the most important section to attract a reader's attention. Please ensure you include a brief background to the problem, the method for your quality improvement project, the overall results and | Title Page 1 Abstract, Pages 2-3 | | | | |
| | | | | conclusion. | | | | | |
| Introduction | | | | | | | | | |
| Background rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Introduction, Pages 4-5 | Background information about the problem and up-to- date, research and knowledge from the literature. | Introduction, Pages 4-5 | | | | |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Introduction, Page 4-5 | Summarise your problem and the focus of your project. | Introduction, Page 4-5 | | | | |
| Methods | • | | | • | • | | | | |
| Study Design | 4 | Present key elements of study design early in the paper | Methods, Page 5 | Describe any reasons or assumptions that were used to develop the intervention(s) and reasons why you expected them to work. | Methods, Pages 5-6 | | | | |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Methods, Page 5 | | | | | | |
| Participants | 6 | (a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of | Methods, Page 5 | | | | | | |

| | | participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods | Methods, Page 5 | | |
|------------------------------|----|---|-----------------------|--|-----------------------|
| | | of selection of participants (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of | | | |
| Variables | 7 | controls per case Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | Methods, Pages 5-6 | Explain your strategy for improvement and discuss how you implemented your study. | Methods, Pages 5-6 |
| Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Methods, Pages 5-6 | | |
| Bias | 9 | Describe any efforts to address potential sources of bias | Methods, Pages 5-6 | | |
| Study size | 10 | Explain how the study size was arrived at | Methods, Pages 5-6 | | |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the | Methods, Pages 5-6 | | |

| | | 1 | I | | |
|------------------------|----|--|-----------------------|--|--|
| | | analyses. If applicable, describe which groupings were chosen, and why | | | |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study - If applicable, explain how loss to follow-up was addressed Case-control study - If applicable, explain how matching of cases and controls was addressed Cross-sectional study If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses | Methods, Page 6 | | |
| Participants | 13 | (a) Report the numbers of individuals at each stage of the study (<i>e.g.</i>, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram | Methods, Pages 6-7 | | |
| Descriptive data | 14 | (a) Give characteristics of study participants (<i>e.g.</i> , demographic, | Results, pages 6-7 | | |

| | | | 1 | | 1 |
|-----------------|----|---|--------------------|---|--------------------------|
| | | clinical, social) and | | | |
| | | information on | | | |
| | | exposures and | | | |
| | | potential confounders | | | |
| | | (b) Indicate the | | | |
| | | number of | | | |
| | | participants with | | | |
| | | missing data for each | | | |
| | | variable of interest | | | |
| | | (c) Cohort study - | | | |
| | | summarise follow-up | | | |
| | | time (<i>e.g.</i> , average | | | |
| | | and total amount) | | | |
| Outcome data | 15 | Cohort study - Report | Results, | | |
| Outcome data | 15 | numbers of outcome | Page 7 | | |
| | | | 1 age 7 | | |
| | | events or summary measures over time | | | |
| | | | | | |
| | | Case-control study - | | | |
| | | Report numbers in | | | |
| | | each exposure | | | |
| | | category, or summary | | | |
| | | measures of exposure | | | |
| | | Cross-sectional study | | | |
| | | - Report numbers of | | | |
| | | outcome events or | | | |
| | | summary measures | | | |
| Main results | 16 | (a) Give unadjusted | Results, Page | Provide a summary of what | Results, |
| | | estimates and, if | 7 | your results showed. | pages 6-7 |
| | | applicable, | | Comment on whether there | |
| | | confounder-adjusted | | were any unintended | |
| | | estimates and their | | consequences such as | |
| | | precision (e.g., 95% | | unexpected benefits, | |
| | | confidence interval). | | problems, failures or costs | |
| | | Make clear which | | associated with the | |
| | | confounders were | | intervention(s). | |
| | | adjusted for and why | | | |
| | | they were included | | | |
| | | (b) Report category | | | |
| | | boundaries when | | | |
| | | continuous variables | | | |
| | | were categorized | | | |
| | | nere cutegorized | | | |
| | | (c) If relevant | | | |
| | | (c) If relevant, | | | |
| | | consider translating | | | |
| | | consider translating estimates of relative | | | |
| | | consider translating estimates of relative risk into absolute risk | | | |
| | | consider translating estimates of relative risk into absolute risk for a meaningful time | | | |
| Other on a last | 17 | consider translating estimates of relative risk into absolute risk for a meaningful time period | Decults | | |
| Other analyses | 17 | consider translating estimates of relative risk into absolute risk for a meaningful time period Report other analyses | Results, | | |
| Other analyses | 17 | consider translating estimates of relative risk into absolute risk for a meaningful time period Report other analyses done—e.g., analyses | Results, Page 7 | | |
| Other analyses | 17 | consider translating estimates of relative risk into absolute risk for a meaningful time period Report other analyses done—e.g., analyses of subgroups and | | | |
| Other analyses | 17 | consider translating estimates of relative risk into absolute risk for a meaningful time period Report other analyses done—e.g., analyses of subgroups and interactions, and | | | |
| | 17 | consider translating estimates of relative risk into absolute risk for a meaningful time period Report other analyses done—e.g., analyses of subgroups and | | | |
| Discussion | | consider translating estimates of relative risk into absolute risk for a meaningful time period Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | Page 7 | | |
| | 17 | consider translating estimates of relative risk into absolute risk for a meaningful time period Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses Summarise key | Page 7 Discussion, | Comment on the strengths of | Discussion, |
| Discussion | | consider translating estimates of relative risk into absolute risk for a meaningful time period Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | Page 7 | Comment on the strengths of the project. Describe any | Discussion, pages 7-8 |

| | | | | problems you faced and how you navigated these. | |
|------------------|----|---|--------------------------|---|--------------------------|
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discussion, Page 8 | Reflect on your project's limitations. | Discussion, Page 8 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Discussion, Pages 7-8 | Describe whether chance, bias, or confounding have affected your results and whether there was any imprecision in the design or analysis of the project. Are more data points required? | Discussion, Pages 7-8 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Discussion, Page 7-8 | Comment on the limits of generalisability. | Discussion, Page 7-8 |
| Conclusions | | <u> </u> | | | |
| | | | | The point of the conclusion is not to rewrite the whole project, but to give an overview of how the whole project was conducted, what it achieved, and some personal reflections. | Conclusions Pages 8-9 |
| Other Informati | 1 | | T | | 1 |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 8 | | |